A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs VX 15 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Proof of concept
- Acronyms SIGNAL
- Sponsors Vaccinex
- 11 Oct 2017 Planned number of patients changed from 116 to 240.
- 11 Oct 2017 Planned End Date changed from 1 Mar 2020 to 1 May 2020.
- 11 Oct 2017 Planned primary completion date changed from 1 Jun 2019 to 1 May 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History